Universe Historical Financial Ratios
UPC Stock | USD 0.64 0.04 5.88% |
Universe Pharmaceuticals is promptly reporting on over 86 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 1.75, Dividend Yield of 0.0096, PTB Ratio of 1.43 or Days Sales Outstanding of 90.28 will help investors to properly organize and evaluate Universe Pharmaceuticals financial condition quickly.
Universe |
About Universe Financial Ratios Analysis
Universe PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Universe Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Universe financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Universe Pharmaceuticals history.
Universe Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Universe Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Universe Pharmaceuticals sales, a figure that is much harder to manipulate than other Universe Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Universe Pharmaceuticals dividend as a percentage of Universe Pharmaceuticals stock price. Universe Pharmaceuticals dividend yield is a measure of Universe Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an Universe Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Universe Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Universe Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.At present, Universe Pharmaceuticals' Days Of Inventory On Hand is projected to decrease significantly based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 6.70, whereas Price To Sales Ratio is forecasted to decline to 1.75.
2023 | 2024 (projected) | Dividend Yield | 0.009169 | 0.009627 | Price To Sales Ratio | 1.84 | 1.75 |
Universe Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Universe Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Universe Pharmaceuticals fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 51.17 | 16.79 | 4.59 | 1.6 | 1.84 | 1.75 | |
Ptb Ratio | 75.52 | 13.67 | 3.97 | 1.31 | 1.5 | 1.43 | |
Days Sales Outstanding | 129.24 | 120.27 | 138.06 | 121.21 | 109.09 | 90.28 | |
Book Value Per Share | 5.66 | 16.26 | 12.81 | 10.91 | 9.82 | 6.59 | |
Free Cash Flow Yield | 0.003859 | (0.0193) | (0.007628) | 0.0208 | 0.0187 | 0.0197 | |
Operating Cash Flow Per Share | 1.66 | (0.57) | (0.36) | 0.31 | 0.36 | 0.34 | |
Capex To Depreciation | 0.13 | 30.28 | 0.18 | 0.0868 | 0.0781 | 0.0742 | |
Pb Ratio | 75.52 | 13.67 | 3.97 | 1.31 | 1.5 | 1.43 | |
Ev To Sales | 50.93 | 16.72 | 4.55 | 1.6 | 1.85 | 1.75 | |
Free Cash Flow Per Share | 1.65 | (4.3) | (0.39) | 0.3 | 0.34 | 0.19 | |
Roic | 0.51 | 0.33 | 0.18 | (0.15) | (0.13) | (0.14) | |
Inventory Turnover | 8.71 | 9.2 | 8.27 | 6.58 | 5.92 | 5.62 | |
Net Income Per Share | 2.06 | 3.12 | (2.41) | (1.7) | (1.96) | (1.86) | |
Days Of Inventory On Hand | 41.89 | 39.67 | 44.13 | 55.48 | 63.81 | 78.01 | |
Payables Turnover | 6.17 | 4.27 | 5.93 | 4.8 | 5.52 | 6.7 | |
Sales General And Administrative To Revenue | 0.0404 | 0.0687 | 0.0437 | 0.0686 | 0.0618 | 0.0357 | |
Research And Ddevelopement To Revenue | 0.019 | 0.11 | 0.19 | 0.15 | 0.14 | 0.0694 | |
Capex To Revenue | 0.001687 | 0.28 | 0.002334 | 0.001367 | 0.00123 | 0.001169 | |
Cash Per Share | 2.74 | 6.01 | 5.2 | 5.1 | 4.59 | 2.7 | |
Pocfratio | 256.91 | (391.97) | (140.46) | 46.12 | 53.04 | 50.38 | |
Interest Coverage | 82.84 | 133.76 | (43.22) | (22.49) | (25.87) | (24.57) | |
Capex To Operating Cash Flow | 0.00847 | (6.58) | (0.0714) | 0.0394 | 0.0454 | 0.0476 | |
Pfcf Ratio | 259.11 | (51.7) | (131.1) | 48.01 | 55.21 | 52.45 | |
Days Payables Outstanding | 59.14 | 85.56 | 61.5 | 76.1 | 68.49 | 51.86 | |
Income Quality | 1.75 | 0.81 | (0.18) | 0.15 | (0.21) | (0.2) | |
Roe | 0.36 | 0.19 | (0.19) | (0.16) | (0.18) | (0.17) | |
Ev To Operating Cash Flow | 255.7 | (390.15) | (139.11) | 46.29 | 53.24 | 50.58 | |
Pe Ratio | 207.86 | 71.19 | (21.1) | (8.38) | (9.64) | (9.16) | |
Return On Tangible Assets | 0.43 | 0.26 | 0.16 | (0.15) | (0.12) | (0.13) | |
Ev To Free Cash Flow | 257.89 | (51.46) | (129.84) | 48.19 | 55.42 | 52.65 | |
Earnings Yield | 0.004811 | 0.014 | (0.0474) | (0.12) | (0.14) | (0.13) | |
Intangibles To Total Assets | 0.006068 | 0.002544 | 0.002644 | 0.002788 | 0.003207 | 0.005537 | |
Net Debt To E B I T D A | (0.7) | (0.26) | 0.24 | (0.0613) | (0.0552) | (0.058) | |
Current Ratio | 2.91 | 4.5 | 3.17 | 2.68 | 2.41 | 2.22 | |
Tangible Book Value Per Share | 5.61 | 16.21 | 12.77 | 10.86 | 9.78 | 6.56 | |
Receivables Turnover | 2.82 | 3.03 | 2.64 | 3.01 | 3.46 | 3.74 | |
Graham Number | 16.18 | 33.8 | 26.36 | 20.42 | 18.38 | 14.82 | |
Shareholders Equity Per Share | 5.66 | 16.26 | 12.81 | 10.91 | 9.82 | 6.59 | |
Debt To Equity | 0.13 | 0.0735 | 0.0848 | 0.14 | 0.16 | 0.17 | |
Capex Per Share | 0.0141 | 3.73 | 0.0258 | 0.0122 | 0.011 | 0.0104 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Universe Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.82) | Earnings Share (76.35) | Revenue Per Share 7.351 | Quarterly Revenue Growth (0.30) | Return On Assets (0.06) |
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Universe Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.